Biotech

All Articles

Neurocrine's KarXT rival strikes in stage 2-- but only at reduced dosage

.Neurocrine Biosciences has attained its own hoped-for profile page in a stage 2 schizophrenia trial...

Vaderis' rare capillary disorder drug reduces nosebleeds

.Vaderis Rehabs' goal to cultivate the very first medicine striven particularly at a specific uncomm...

Navigator rears $100M to cultivate brand new autoimmune pipeline

.Navigator Medicines has furnished on its own along with $100 million in series A funds as the youth...

Duality finds cash money for ADC tests as IPO surge infects Asia

.China's Duplicity Biotherapeutics has filed (PDF) documentation for a Hong Kong IPO, seeking an unr...

YolTech sells China rights to genetics editing therapy for $29M

.Four months after Mandarin gene modifying provider YolTech Therapies took its own cholesterol disea...

Addex inventory rises after Indivior offers up to $300M for material

.Indivior is actually grabbing a little particle allosteric modulator tailored to address drug use p...

Molecular Allies modifies AML test over 'suboptimal exposure'

.Molecular Partners has pinpointed "suboptimal direct exposure" to its own tetra-specific T-cell eng...

Despite mixed market, a venture capital revival could be can be found in Europe: PitchBook

.While the biotech expenditure scene in Europe has reduced relatively adhering to a COVID-19 financi...

8 months after a $213M fundraise, genetics publisher Tome produces decreases

.After raising $213 million in 2023-- among the year's biggest exclusive biotech rounds-- Volume Bio...

BioMarin creates director group with biotech veterinarians-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of substantial management hirings, firings a...